July 25, 2024 – Page 16 – Goldea Capital

Groupe Casino: TotalEnergies and Casino renew their partnership for supplying over 1,000 service stations in France

Written by Customer Service on July 25, 2024. Posted in Public Companies.

Press release25 July 2024 TotalEnergies and Casino renew their partnership for supplying over 1,000 service stations in France Casino Group and TotalEnergies have announced the renewal of their strategic partnership for supplying more than 1,000 service stations in France. The new agreement, consolidating a partnership of over 20 years between the two companies, will come into force on 1 October 2024 for a duration of five years1. The partnership includes: A nationwide presence: Casino will continue to supply food products and other essential items to more than 1,000 TotalEnergies service stations, nearly 140 of which are located on motorways. A wide range of services: Casino will supply the TotalEnergies service station network in three ways: as a supplier of food products, as a supplier of Casino products and through “Casino Shop” or...

More than 1.5 Million Higher Education Students in the U.S. Now Rely on Quadient Smart Lockers for Package Delivery

Written by Customer Service on July 25, 2024. Posted in Public Companies.

Parcel Pending by Quadient Automated Lockers at Valencia College. Parcel Pending by Quadient automated lockers at Valencia College. Parcel Pending by Quadient automated lockers are now installed at more than 250 higher education institutions across the country Paris Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today it has reached a new milestone of installed smart lockers totaling more than 250 colleges and universities across the United States. Across the campuses, more than 1.5 million students per year are served by the automated lockers. Higher education institutions using the Parcel Pending by Quadient automated locker platform range from large universities with tens of thousands of students to smaller colleges with hundreds. Institutions include...

Air France-KLM – Financial statements and notes to the financial statements as of June 30, 2024

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

Air France-KLM – Financial statements and notes to the financial statements as of June 30, 2024 Attachment 2024.06 – Air France-KLM – Financial statements and notes to the financial statements as of June 30, 2024

Air France-KLM Half Year Results

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

xx SECOND QUARTER 2024 July 25, 2024 Operating result of €513 million with operating margin at 6.5% impacted by unit cost and higher fuel price Group capacity increased by 4.1% compared to last year with load factor at 88% Group revenues at €7.9bn, up 4.3% compared to last year Unit cost at +1.7% compared to 2023 Operating result at €513m, with operating margin at 6.5%, Olympic Games impact €40m Half-Year Recurring adjusted operating free cash flow positive at €134m Cash at hand at €9.6bn and Net debt/EBITDA ratio of 1.6x Commenting on the results, Mr. Benjamin Smith, Group CEO, said: “The second quarter of 2024 confirmed an increasingly challenging environment for aviation, with rising fuel prices and a continued pressure on costs. In this context, KLM and Transavia delivered a stable yet sluggish performance, while Air France...

With Important Product-Led Transition Year Underway, Stellantis Delivers €5.6 Billion Net Profit, €8.5 Billion AOI and 10% AOI Margin in the First Half of 2024

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

With Important Product-Led Transition Year Underway, Stellantis Delivers €5.6 Billion Net Profit, €8.5 Billion AOI(1) and 10% AOI Margin(2) in the First Half of 2024 Net revenues of €85.0 billion, down 14% compared to H1 2023, primarily due to the decline in volume and mix Net profit of €5.6 billion, down 48% compared to H1 2023, primarily due to lower volume and mix, headwinds from foreign exchange and restructuring costs Adjusted operating income(1) of €8.5 billion, down €5.7 billion compared to H1 2023, primarily due to decreases in North America AOI margin(2) of 10%, reflecting direct materials, workforce and logistics cost reductions which helped to mitigate the revenue decline Management taking decisive actions to address operational challenges, including North American share and inventory performance Industrial free cash flows(3)...

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

PARIS, FRANCE, 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024. Business highlights U.S. regulatory approvals and launches of Onivyde® (irinotecan) in first-line pancreatic cancer and Iqirvo® (elafibranor) in second-line primary biliary cholangitis, respectively In-licensing of tovorafenib outside the U.S.: an attractive addition to our Oncology pipeline Multiple early-stage external-innovation transactions across Oncology and Neuroscience Financial highlights Total-sales growth of 9.5% at CER1, or 8.0% as reported, driven by the performances of Cabometyx® (cabozantinib) and Dysport® (abobotulinumtoxinA), as well as contributions from Bylvay® (odevixibat) and Onivyde Core operating margin of 32.4%, a decline...

Arcadis Q2 and Half Year 2024 Results: Continued growth and improved operating margin as 2024-2026 strategy implementation commenced

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

PRESS RELEASE Arcadis Second Quarter and Half Year Results 2024Continued growth and improved operating margin as 2024-2026 strategy implementation commenced SECOND QUARTER RESULTS Net revenue of €991 million, solid organic growth of 6.0%1) Strong order intake of €1.1B resulting in organic backlog growth of 5.6% year-on-year Improved operating EBITA margin2) to 11.5% (Q2’23: 9.7%3)) driven by operating leverage and improved project portfolio Free cash flow of €8 million (Q2‘23: €-26M), net working capital % of 12.7% (Q2‘23: 12.2%3)) Amsterdam, 25 July 2024 – Arcadis, the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, sees continued growing client demand across all its business, resulting in net revenue of €991 million, organic growth of 6% and an...

STMicroelectronics Reports 2024 Second Quarter Financial Results

Written by Customer Service on July 25, 2024. Posted in Earnings Releases And Operating Results.

STMicroelectronics Reports 2024 Second Quarter Financial Results Q2 net revenues $3.23 billion; gross margin 40.1%; operating margin 11.6%; net income $353 million H1 net revenues $6.70 billion; gross margin 40.9 %; operating margin 13.8%; net income $865 million Business outlook at mid-point: Q3 net revenues of $3.25 billion and gross margin of 38% Geneva, July 25, 2024 – STMicroelectronics N.V. (“ST”) (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, reported U.S. GAAP financial results for the second quarter ended June 29, 2024. This press release also contains non-U.S. GAAP measures (see Appendix for additional information). ST reported second quarter net revenues of $3.23 billion, gross margin of 40.1%, operating margin of 11.6%, and net income of $353 million or $0.38...

Vidac Pharma publishes results of next-generation drug candidate tests in human and murine tumor models

Written by Customer Service on July 25, 2024. Posted in Public Companies.

London (UK), July 25, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces that promising results of its study with VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumors are now available online, as a preprint submitted to peer review. The study showed that VDA-1275 showed statistically significant efficacy as a monotherapy, as well as synergistic effects in combination with two standard-of-care cancer treatments, and that it moreover induced an immunologic response. The main findings of the study were that VDA-1275: reinstates apoptosis (programmed cell death), halts rapid proliferation of cancer cells, reduces the hyper-glycolytic metabolism...

Huhtamäki Oyj’s Half-yearly Report January 1–June 30, 2024: Continued improvement in operational profitability

Written by Customer Service on July 25, 2024. Posted in Public Companies.

HUHTAMÄKI OYJ HALF-YEARLY REPORT 25.7.2024 AT 8.30 EEST Q2 2024 in brief Net sales decreased 1% to EUR 1,038 million (EUR 1,052 million) Comparable net sales growth at Group level was -1% Reported EBIT was EUR 105 million (EUR 55 million); adjusted EBIT was EUR 106 million (EUR 93 million) Reported EPS was EUR 0.62 (EUR 0.24); adjusted EPS was EUR 0.63 (EUR 0.55) The impact of currency movements on the Group’s net sales was EUR -6 million and EUR -1 million on EBIT H1 2024 in brief Net sales decreased 3% to EUR 2,041 million (EUR 2,099 million) Comparable net sales growth at Group level was -2% Reported EBIT was EUR 182 million (EUR 142 million); adjusted EBIT was EUR 204 million (EUR 185 million) Reported EPS was EUR 0.97 (EUR 0.72); adjusted EPS was EUR 1.17 (EUR 1.06) The impact of currency movements on the Group’s net sales was...

Day: July 25, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice